koryu

crispr crispr

Long
koryu Aggiornato   
NASDAQ:EDIT   Editas Medicine, Inc.
15
Follow up idea, see related idea

After 5 wave impulse down and two month accumulation phase below IPO level sideways,
expect trend reversal into bull market, the downtrend channel got broken and tested on weekly timeframe.
The first human got crispered in china. USA will follow in 2017, I speculate on public awareness and solid growth, maybe hype.

In case of bull market, we got the possible pitchfork
Commento:
and back above IPO!!! i love it <3
Commento:
look for rsi breakout into new highs, consolidation above 18$ would confirm reversal.

Commento:
Wyckoff scenario
Commento:
wyckoff playing out nicely, can buy on dips for reaccumulation 16-17$ range
trailing stop below pitchfork, this stock keeps giving for weeks now with great volatility
Commento:
made a little indicator to compare EDIT price with the BTK biotech index
At ipo the indicator is 0, values below 0 indicates that EDIT is undervalued compared to biotech index, values over 0 indicates EDIT is overvalued compared to biotech index. Also showing the MA20 of this line (black).

Commento:
Commento:
crispr again in the news after
Commento:
crispr again on all news sites after National Academy of Sciences releases Report "Human Genome Editing: Science, Ethics, and Governance"
Commento:
CRISPR patent goes to Broad Institute of Cambridge -> EDIT www.technologyreview...-to-broad-institute/
Commento:
pitchfork still intact!

wyckoff scenario also playing out as expected :-)

Commento:
Editas Medicine announces that its offering of 4M shares priced at $22.50 per share.
seekingalpha.com/new...-prices-90m-offering

resistance 0.5 fib keylevel at 28.20
Support 20.00-22.50
Commento:
doubled my position here
Commento:
this should be a bear trap, new chart on linear scale

Declinazione di responsabilità

Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.